Gilmore Neil O'Neill Editas Medicine, Inc. (EDIT) insider trading activity

Gilmore Neil O'Neill is CEO of Editas Medicine, Inc.. Currently has a direct ownership of 269,087 shares of EDIT, which is worth approximately $699,626. The most recent transaction as insider was on Dec 03, 2025, when has been sold 5,603 shares (Common Stock) at a price of $2.15 per share, resulting in proceeds of $12,046. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 269K

2.04% 3M change

13.78% 12M change

Total Value Held $699,626

Gilmore Neil O'Neill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 03 2025	SELL Open market or private sale	$12,046 $2.15 p/Share	5,603 Reduced 2.04%	269,087 Common Stock
Sep 03 2025	SELL Open market or private sale	$14,539 $2.6 p/Share	5,592 Reduced 2.0%	274,690 Common Stock
Jun 03 2025	SELL Open market or private sale	$26,130 $1.72 p/Share	15,192 Reduced 5.14%	280,282 Common Stock
Mar 04 2025	SELL Open market or private sale	$28,440 $1.71 p/Share	16,632 Reduced 5.33%	295,474 Common Stock
Dec 03 2024	SELL Open market or private sale	$3,365 $2.08 p/Share	1,618 Reduced 0.52%	312,106 Common Stock
Sep 04 2024	SELL Open market or private sale	$5,318 $3.42 p/Share	1,555 Reduced 0.49%	313,724 Common Stock
Jun 04 2024	SELL Open market or private sale	$67,050 $5.5 p/Share	12,191 Reduced 3.72%	315,279 Common Stock

Mar 05 2024	SELL Open market or private sale	$733,102 $9.42 p/Share	77,824 Reduced 19.2%	327,470 Common Stock
Mar 02 2024	BUY Grant, award, or other acquisition	-	275,125 Added 40.43%	405,294 Common Stock
Jun 05 2023	SELL Open market or private sale	$61,617 $9.5 p/Share	6,486 Reduced 4.75%	130,169 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	50,000 Added 26.79%	136,655 Common Stock
Jun 02 2022	BUY Grant, award, or other acquisition	-	86,655 Added 50.0%	86,655 Common Stock

Also insider at

UBX

Unity Biotechnology, Inc. Healthcare

SRPT

Sarepta Therapeutics, Inc. Healthcare

EVP, R&D & CMO

APTX

Aptinyx Inc. Healthcare

GNO